Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Epigenetic Biomarker

  • Tina Bianco-Miotto
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7134-5


Epigenetic biomarker refers to the measurement of epigenetic modifications in tissues or peripheral fluids like urine, blood, plasma, serum, and stool samples, as markers of disease detection, progression, and therapy response. In particular, most research into epigenetic biomarkers has focused on assessing epigenetic modifications as markers of diagnosis, prognosis, and therapy response in cancers. However, epigenetic biomarkers have also been used as markers of disease (e.g., Alzheimer, Parkinson, diabetes, obesity), and other uses have included markers of response to environmental exposures and toxicology.


Epigenetic Modifications

Epigenetic changes include DNA methylation, histone modifications, and noncoding RNA which includes microRNAs. Epigenetic changes result in changes in gene expression without alterations to the DNA sequence. DNA methylation is the addition of a methyl group to the 5′ carbon of a cytosine, which occurs predominantly at cytosine...


Prostate Cancer Histone Modification Epigenetic Modification Epigenetic Change Noncoding RNAs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome – biological and translational implications. Nat Rev Cancer 11:726–734CrossRefPubMedPubMedCentralGoogle Scholar
  2. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R (2005) Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 11:6582–6588CrossRefPubMedGoogle Scholar
  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  4. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10:8472–8478CrossRefPubMedGoogle Scholar
  5. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 91:11733–11737CrossRefPubMedPubMedCentralGoogle Scholar
  6. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM (2003) Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 163:923–933CrossRefPubMedPubMedCentralGoogle Scholar
  7. Neal DE, Donovan JL (2000) Prostate cancer: to screen or not to screen? Lancet Oncol 1:17–24CrossRefPubMedGoogle Scholar
  8. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262–1266CrossRefPubMedGoogle Scholar
  9. Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM (2011) Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 105:65–73CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Robinson Research Institute and School of Agriculture, Food and WineThe University of AdelaideAdelaideAustralia